Thiopurines in IBD: What is their mechanism of action?

Gastroenterology and Hepatology

Volumn 6, Issue 7, 2010, Pages 435-436

  Neurath, Markus ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; DNA; DRUG METABOLITE; MERCAPTOPURINE; RAC1 PROTEIN; TIOGUANINE;

CANCER RISK; CROHN DISEASE; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG METABOLISM; ENTERITIS; HUMAN; LIVER TOXICITY; LYMPHOMA; NOTE; TREATMENT OUTCOME;

EID: 77956828371     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. Atreya I, Neurath MF. Understanding the delayed onset of action of azathioprine in IBD: are we there yet? Gut. 2009;58:325-326.
2. Poppe D, Tiede I, Fritz G, et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol. 2006;176:640-651. (Pubitemid 43023313)
3. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111:1133-1145.
4. Ben-Horin S, Goldstein I, Fudim E, et al. Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines. Gut. 2009;58:396-403.
5. Kotelitz BI, Present DH. A history of immunosuppressive drugs in the treatment of inflammatory bowel disease: origins at the Mount Sinai Hospital. Mt Sinai J Med. 1996;63:191-201.